Registry of Lobbyists

Registration - In-house Corporation

GlaxoSmithKline / Sridhar Venkatesh, General Manager and President

Registration Information

In-house Corporation name: GlaxoSmithKline
Previous in-house corporation names
Responsible Officer Name: Sridhar Venkatesh, General Manager and President 
Responsible Officer Change History
Initial registration start date: 1996-03-25
Registration status: Active
Registration Number: 953603-5088

Associated Communications

Total Number of Communication Reports: 285

Monthly communication reports in the last 6 months: 19

Version 3 of 65 (1998-02-13 to 1999-01-21)

Version 3 of 65 (1998-02-13 to 1999-01-21) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Lobbyist and Corporation

Corporation: GLAXOSMITHKLINE
7333 MISSISSAUGA ROAD NORTH
MISSISSAUGA, ON  L5N 6L4
Canada
Telephone number: 905-819-3030
Fax number: 905-819-3097  
Responsible officer name and position during the period of this registration: PAUL N LUCAS, PRESIDENT & CEO  
Description of activities: GLAXO WELLCOME INC. IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. IT'S BRITISH PARENT, GLAXO PLC, AMALGAMATED WITH WELLCOME PLC IN MARCH, 1995 TO CREATE THE WORLD'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANY.GLAXO WELLCOME OPERATES 3 MAIN FACILITIES IN CANADA, INCLUDING ITS BUREAU D'AFFAIRES DU QUEBEC IN MONTREAL, AND EMPLOYS MORE THAN 1100 PEOPLE ACROSS THE COUNTRY.GLAXO WELLCOME IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING CARDIOVASCULAR, HIV/ AIDS, GASTRO-INTESTINAL, RESPIRATORY DISEASES & ANTI-INFECTIVE.GLAXO WELLCOME INVESTS MORE THAN $50 MILLION IN RESEARCH & DEV. IN CANADA ANNUALLY. IN ADDITION, GLAXO WELLCOME CONDUCTS ALMOST $10 MILLION IN CLINICAL RESEARCH ANNUALLY TO EVALUATE DRUGS FOR AIDS, ASTHMA, MIGRAINE, INFLUENZA, NAUSEA & VOMITING.GLAXO WELLCOME'S MANUFACTURING OPERATIONS SERVE BOTH CANADIAN & AMERICAN MARKETS.
 
The client is a subsidiary of the following parent companies: GLAXO WELLCOME PLC
LANDSDOWN HOUSE, BERKELEY SQUARE
LONDON W1XGBP
United Kingdom

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Environment Canada, Federal Environmental Assessment Review Office (FEARO), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Patented Medicine Prices Review Board (PMPRB), Social Sciences and Humanities Research Council (SSHRC), Treasury Board Of Canada Secretariat (TBS), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Consumer Issues, Employment and Training, Environment, Health, Industry, Intellectual Property, International Relations, International Trade, Regional Development, Science and Technology, Taxation and Finance
 
Subject Matter: Particulars: ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION, SUCH AS BILL C-91; HOMECARE AND PHARMACARE PROGRAMS; DRUG APPROVALS POLICIES AND PROCESSES.




Date Modified: